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Abstract
Background: Accumulation of amyloid b-peptide (Ab) in the plaques is one of the major pathological features in
Alzheimer’s disease (AD). Sequential cleavage of amyloid precursor protein (APP) by b-site APP cleaving enzyme 1
(BACE-1) and g-secretase results in the formation of Ab peptides. Preventing Ab formation is believed to attenuate
AD progression and BACE-1 and g-secretase are thus attractive targets for AD drug development.
Methods: Combining BACE-1 and g-secretase inhibition on Ab secretion from human neuroblastoma SH-SY5Y cells
was evaluated in this study. Secreted Ab40 and Ab42 levels were measured from SH-SY5Y cells stably transfected
with APPwt or APPswe genes. A selective BACE inhibitor and the g-secretase inhibitor LY450139 (semagacestat)
were used to inhibit respective secretase.
Results: LY450139 increased Ab40 and Ab42 secretion from SH-SY5Y APPwt cells at low concentrations (by 60% at
3 nM) followed by subsequent inhibition at higher concentrations (IC50 90 nM). Washout studies showed that the
Ab increase evoked by 3 nM LY450139 was not due to enhanced cleavage following substrate accumulation but
rather to activation of Ab formation. By contrast, LY450139 inhibited Ab formation from SH-SY5Y APPswe in a
monophasic manner (IC50 18 nM). The BACE inhibitor per se inhibited Ab secretion from both SH-SY5Y APPwt and
SH-SY5Y APPswe cells with IC50s ranging between 7 - 18 nM and also prevented the increased Ab secretion
evoked by 3 nM LY450139. Combining the BACE inhibitor with higher inhibitory concentrations of LY450139 failed
to demonstrate any clear additive or synergistic effects.
Conclusion: BACE-1 inhibition attenuates the Ab increase evoked by LY450139 while not providing any obvious
synergistic effects on LY450139-mediated inhibition.
Background
Alzheimer’s disease (AD) is the most common form of
dementia in human with amyloid plaques and neurofi-
brillary tangles being hallmark features. The enzymatic
cascade involved in the formation of Ab1-40 and Ab1-
42 peptides, the predominant species of plaques, has
been characterized in detail (for a recent review see [1]).
Amyloid precursor protein (APP) is cleaved by b-site
APP cleaving enzyme-1 (BACE-1) followed by subse-
quent cleavage by the g-secretase complex to form Ab
peptides. It is still not clear what the assumed neuro-
toxic agent is, although recent data suggest Ab dimers
and oligomers as being the most neurotoxic Ab assem-
blies [2].
Nonetheless, it is widely believed that inhibiting the
formation of Ab, either by inhibiting BACE-1 or g-secre-
tase would be of benefit for AD patients, regardless
which Ab assembly is the neurotoxic agent. Quite some
progress has been made with respect to g-secretase inhi-
bition. The furthest advanced compound LY450139
(semagacestat) was shown to lower Ab levels in the cer-
ebrospinal fluid from healthy volunteers [3]. Other g-
secretase inhibitors have achieved similar results clini-
cally. Hence, central efficacy appears clinically feasible
with this class of drugs. However, safety issues have
been raised by inhibiting this drug target since g-secre-
tase also cleaves Notch protein, a substrate that plays an
important role in cellular differentiation. Indeed, g-
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any medium, provided the original work is properly cited.secretase inhibitors have produced hyperplasia of intest-
inal Goblet cells and altered tissue morphology in
rodents [4,5]. Also, inhibitors cause thymus atrophy pre-
clinically [5] and reduce circulating B cells in patients
[6]. Two subsequent g-secretase inhibitors, begacestat
[7] and BMS708163 [8], with improved selectivity
towards Notch have reached clinical development.
Nonetheless, Notch liabilities may limit the doses that
can be given safely.
Inhibition of g-secretase leads to Ab reductions in
plasma and in brain if desired compound levels are
reached. Interestingly, after lowering Ab levels at effica-
cious doses, Ab subsequently rise to levels substantially
higher than baseline levels, often referred to as a
rebound effect. However, low, sub-efficacious doses of g-
secretase inhibitor also appear to increase Ab levels put-
ting the mechanism behind the rebound phenomena
into question and instead suggesting an Ab rise at low
concentrations without previous inhibition. This Ab rise
phenomena has mainly been demonstrated in plasma in
mice, guinea pigs, beagle dogs and healthy human
volunteers [9-11] but also in cerebrospinal fluid in gui-
nea pigs [10] and in rat brains [12]. The Ab rebound/
rise phenomena seems to be a target class-related effect,
since similar findings have been demonstrated with che-
mically distinct g-secretase inhibitors [7]. However, a
recently characterized g-secretase inhibitor, PF-3084014
appears to lack this attribute preclinically [13]. The pos-
sible impact of Ab rebound/rise on AD disease progres-
sion is unknown; however it is not inconceivable that
non-compliant patients could be exposed to sub-effica-
cious levels of g-secretase inhibitor resulting in elevated
concentrations of Ab. Recently, a phase III clinical trial
with LY450139 (semagacestat) in AD patients was dis-
continued prematurely [14]. Surprisingly it was reported
that patients receiving LY450139 fared worse than pla-
cebo-treated controls with respect to cognitive
symptoms.
Less progress has been made with respect to BACE-1
inhibition. Although BACE inhibitors reduce Ab levels
in brain or cerebrospinal fluid in PgP KO mice [15],
APP transgenic mice [16-18], wild type mice [19] and
rhesus monkey [20], there is limited data demonstrating
central Ab-lowering effects in man. The lack of progress
of clinical BACE inhibitors is due to the difficulty of
combining adequate potency with good PK properties
(e.g. permeability over the BBB, efflux, protein binding,
metabolism).
Considering that 1) g-secretase inhibitors have possible
safety issues which may reduce the doses regarded as
s a f ea n d2 )m o s tg-secretase inhibitors appear to cause
increases of Ab levels at low concentrations and 3) cen-
tral efficacy with BACE inhibitors is difficult to achieve,
t h ea i mo ft h ep r e s e n ts t u d yw a st oe v a l u a t ei fB A C E - 1
inhibition could prevent the Ab rebound/rise evoked by
a g-secretase inhibitor and if synergistic efficacy on Ab
secretion could be achieved by combining BACE and g-
secretase inhibitors.
Materials and methods
Inhibitors
The g-secretase inhibitor (N)-((S)-2-hydroxy-3-methyl-
butyryl)-1-(L-alaninyl)-(S)-amino-3-methyl-2,3,4,5-tetra-
hydro-1H-3-benzazepin-2-one dihydrate (LY450139,
semagacestat) was made in-house as described in Audia
et al. [21]. The BACE-inhibitor N-[(1S,2R)-1-Benzyl-3-
(cyclopropylamino)-2-hydroxypropyl]-7-ethyl-1-methyl-
3,4-dihydro-1H-[1,2,5]thiadiazepino[3,4,5-hi-]indole-9-
carboxamide 2,2-Dioxide (compound 8e in Charrier et
al., 2008) was made in-house as described in Charrier,
et al. [22]. The compound is referred to as “BACE inhi-
bitor” throughout the present paper. The molecular
structures of the BACE inhibitor and LY450139 are
shown in Figure 1.
Cell culture
The human neuroblastoma cell line SH-SY5Y was pur-
chased from European Collection of Cell Cultures
(ECACC). Cells were grown in DMEM/Ham’sF - 1 2
A.
B.
Figure 1 Molecular structures of the inhibitors. A.M o l e c u l a r
structure of the BACE inhibitor as described in Charrier et al., 2008
[22]. B. Structure of the g-secretase inhibitor LY450139
(semagacestat, Audia et al., 2007 [21]).
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(PAA) and 10% Fetal Bovine Serum (PAA). Cells were
maintained at 37°C in a humidified atmosphere contain-
ing 5% CO2.
SH-SY5Y cells were stably transfected with plasmids
carrying human APPwt or APPswe gene. APP gene was
purchased from Geneservice Ltd (clone sequence
BC065529; clone MGC75167) and the APPswe mutation
was generated using a QuikChange
® Site-Directed
Mutagenesis Kit (Stratagene). APPwt and APPswe genes
were cloned into a mammalian expression vector
pcDNA3.1 and the expression was under the control of
CMV promotor. The cells were plated at the density of
6.25 × 10
4 cells/cm
2 in 6-well culture dishes (Sarstedt)
and each well was transfected with 4 μg plasmid DNA.
Lipofectamine™2000 (InVitrogen) was used as a trans-
fection reagent according to manufacturer’s instructions.
The transfected cells were selected with 400 μg/ml
G418 (PAA).
Cells were plated at a density of 6.25 × 10
4 cells/cm
2
in 96-well cell culture plates (TRP) for Ab measure-
ments with ELISA or in 6-well culture dishes (Sarstedt)
for Western blot. The day after the plating of the cells,
the cultures were treated with various concentrations of
g-secretase inhibitor LY450139 or the BACE inhibitor
for 24 hours. Stock solutions of inhibitors were prepared
in dimethyl-sulfoxide (DMSO). All cultures including
the control cells received equal amounts of DMSO, the
final concentration being 0.1%. All the results were from
two to three separate experiments and the data pre-
sented as means ± SEM.
ELISA
The secreted Ab40 and Ab42 peptides in cell culture
media were measured using human amyloid b40 or b42
ELISA kits from Millipore. The absorbance was mea-
sured at 450 nm by Microplate reader (Molecular
Devices). Data from inhibitor-treated cell cultures was
expressed as a percent of untreated controls and the
inhibition curves were analysed by non-linear regression
using Graph Pad Prism.
Western blot
SH-SY5Y cells were lysed in buffer containing 50 mM
Tris-HCl pH 8.0, 150 mM NaCl, 1% Triton X-100, 1 mM
EDTA, 1 mM Na3VO4 and 1 complete protease inhibitor
cocktail tablet (Roche Diagnostics)/10 ml buffer. The cells
were incubated with lysis buffer for 10 minutes on ice
before scraping the cells from the dishes. Cell lysates were
centrifuged at 14 000 rpm for 15 minutes. The protein
content in the supernatants was measured using Pierce
®
660 nm Protein Assay kit. Samples, containing 20 μg pro-
tein, were resolved in 7% NuPAGE
®Tris-Acetate gels
(InVitrogen) using Tris-Acetate SDS running buffer
(InVitrogen). The proteins were transferred to PVDF
membranes using iBlot™ gel transfer stacks (InVitrogen).
Membranes were blocked in PBS with 0.05% Tween 20
containing 3% non-fat dry milk for 1 hour at RT. Mouse b
amyloid (6E10) monoclonal antibody (Signet laboratories)
was diluted 1:1000 and the b-actin antibody (Sigma-
Aldrich) 1:10 000 in 1% milk and incubation was carried
out at 4°C over night. Horseradish-peroxidase (HRP) con-
jugated anti-mouse secondary antibody (Amersham Bios-
ciences) was incubated 1 hour at RT in 1% milk at the
dilution of 1:3000. Blots were developed using the Super
Signal
® detection system (Pierce). Average density of the
bands was measured in ChemiDoc™XRS (Bio-Rad) by
using Quantity One software.
Results
APP expression and Ab secretion from APPwt- and
APPswe-transfected SH-SY5Y cells
Transfection of APPwt and especially APPswe genes
into SH-SY5Y cells increased APP expression compared
to non-transfected cells (Figure 2A). The 6E10 antibody
that binds to amino acid residues 1-16 of Ab recognized
three bands that are most likely isoforms of full-length
APP or mature/immature APP differentially modified by
glycosylation. Densitometric quantification of Western
blot is shown in Figure 2B. The increase in APP level is
approximately 50% in APPwt transfected SH-SY5Y cells
and 100% in APPswe transfected cells.
Baseline secretion of Ab40 and Ab42 during 24 h
from non-transfected SH-SY5Y cells was only slightly
above the level of detection while being readily measur-
able in cells transfected with APPwt (Figure 2C). By
contrast, secreted Ab40 and Ab42 levels were approxi-
mately 15-fold higher from APPswe-transfected cells
compared to APPwt-transfected (Figure 2C). APPswe
gene has a double mutation at codons 670 and 671
located just N-terminal of the Ab N-terminus, which
makes APP a better substrate for BACE resulting in
increased production of total Ab[23].
Effect of the g-secretase inhibitor LY450139 on Ab40 and
Ab42 secretion from SH-SY5Y APPwt and APPswe cells
In SH-SY5Y APPwt cells, the g-secretase inhibitor
LY450139 produced a biphasic response with Ab40
levels increasing in response to low concentrations of
inhibitor, reaching 60% above baseline at 3 nM (Figure
3A). At higher concentrations (> 30 nM), Ab40 levels
decreased with an approximate IC50 of 90 nM. By con-
trast, in SH-SY5Y APPswe cells, LY450139 produced a
concentration-dependent inhibition of Ab40-secretion
with a monophasic profile and an IC50 of 18 nM (Figure
3A). Hence, under our experimental conditions,
LY450139 was ~5-fold less potent at inhibiting Ab40-
secretion from APPwt cells compared to APPswe cells.
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levels by 70% in SH-SY5Y APPwt cells compared to
controls, while secreted Ab42 levels from APPswe cells
were not affected (Figure 3B).
Washout experiments with LY450139 in SH-SY5Y APPwt
and APPswe cells
The previously mentioned experiments were performed
under closed-conditions, i.e. LY450139 was present dur-
ing the whole incubation period (24 h) at a presumed
constant concentration. In order to detect a possible Ab
rebound, we performed washout experiments. Incubat-
ing SH-SY5Y APPwt cells with 300 nM LY450139 for
24 h reduced Ab40 secretion by 80% compared to con-
trol (Figure 4A), consistent with previous results (see
Figure 3A). After 24 h, The LY450139-containing media
a n dc o n t r o lm e d i aw e r ew a s h e do u ta n dr e p l a c e dw i t h
fresh media without inhibitor and Ab40 secretion was
followed for an additional 24 h. In control cells, Ab40
secretion during the subsequent 24 h did not differ
from Ab40 secretion during the initial 24 h indicating
that washout per se does not affect SH-SY5Y secretory
function (Figure 4A). Ab40 secretion during 24 h from
SH-SY5Y APPwt cells that had been pre-treated with
300 nM LY450139-containing media did not differ from
control cells.
In analogy to Ab40, Ab42 secretion from SH-SY5Y
APPwt cells returned to control levels after inhibition
with 300 nM LY450139 for 24 h without any evidence
of a rebound (Figure 4B).
Treatment with 3, 30 or 300 nM LY450139 for 24 h
resulted in accumulation of substrate as shown in Figure
4C with densitometric quantification of the bands sum-
marized in Figure 4D. This suggests that the substrate
accumulation seen during the initial 24 hours did not
lead to excessive Ab40 secretion during the next 24 h.
Shorter time periods (2 - 6 hours) after washout were
also monitored in order to detect any possible immedi-
ate and short-acting Ab40 rebound. However, Ab40
production did not differ between LY450139 pre-treated
and control cells at these shorter time points (data not
shown).
Since 3 nM LY450139 evoked an Ab rise from SH-
SY5Y APPwt cells under standard closed conditions (see
Figure 3A), we wished to evaluate how this low concen-
tration of inhibitor would act following inhibition of Ab
production over 24 h with a high concentration (300
nM) of LY450139 which leads to substrate
A.
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Figure 2 APP expression and Ab secretion in SH-SY5Y cells. A. APP expression in non-transfected, APPwt- and APPswe-transfected SH-SY5Y
cells. The three bands detected with 6E10 antibody in the cell lysates are most likely isoforms of full-length APP or mature/immature APP
differentially modified by glycosylation. B. Densitometric quantification shows 50% increase of APP levels in APPwt transfected SH-SY5Y cells and
100% increase in APPswe transfected cells as compared to non-transfected ones. Data presented as means ± SEM, n = 2. C.A b40 and Ab42
secretion during 24 h in non-transfected, APPwt- and APPswe-transfected SH-SY5Y cells.
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h inhibited Ab secretion by 80% as expected (Figure 5A).
Replacing the medium with 3 nM LY450139 during the
second 24 h incubation period, increased Ab40 levels by
60% compared to the cells that during the first 24 h per-
iod received 300 nM LY450139 and during the second
incubation period received fresh medium (Figure 5A).
This phenomenon was not seen in SH-SY5Y APPswe
cells, where treatment with 300 nM LY450139 followed
by 3 nM LY450139 did not lead to increased Ab40 levels
(Figure 5B). Hence, 3 nM LY450139 evokes a similar
degree of Ab rise in SH-SY5Y APPwt cells, regardless if
cells are pre-treated with a high concentration of inhibi-
tor (leading to substrate accumulation) or not.
Effect of concomitant BACE-1 inhibition on the Ab rise
evoked by LY450139
In SH-SY5Y APPwt cells, the BACE inhibitor inhibited
Ab40-secretion in a concentration-dependent manner
with an IC50 of 7 nM and prevented the Ab rise evoked
by 3 nM LY450139 with an IC50 of 23 nM (Figure 6A).
The BACE inhibitor had a similar potency when con-
structing the concentration response curve in the pre-
sence of 30 nM LY450139 (a concentration which per se
does not affect basal Ab40 levels) as without LY450139
(10 nM vs. 7 nM, Figure 6A). In Figure 6B the same
results (from Figure (6A) are illustrated in an alternative
manner. Here it is highlighted how the LY450139-
evoked Ab40 rise is still present but attenuated in the
presence of 3 nM BACE inhibitor. 30 nM BACE inhibi-
tor was required to abolish the LY450139-evoked Ab40
rise completely.
T h es a m es e r i e so fe x p e r i m e n t sw e r ep e r f o r m e di n
SH-SY5Y APPswe cells. The BACE inhibitor reduced
basal Ab40-secretion from SH-SY5Y APPswe cells in a
concentration-dependent fashion with an IC50 of 18 nM
(Figure 7A). The potency of the BACE inhibitor was
weaker (IC50 110 nM, Figure 7A) in the presence of 3
nM LY450139 (a concentration that does not affect
Ab40-secretion per se - see Figure 3A). The figure high-
lights that 3 nM LY450139, although not producing an
Ab40 rise in APPswe transfected cells, appears to coun-
teract the potency of the BACE inhibitor. In the pre-
sence of 30 nM LY450139, the BACE inhibitor reduced
remaining Ab40 secretion (20-30% remaining) with an
IC50 of 0.2 nM (Figure 7A). Figure 7B illustrates the
data in a different manner. The figure highlights that
overall Ab40 levels are reduced when adding increasing
concentrations of BACE inhibitor, although it seems as
if 3 nM LY450139 under these conditions tends to
increase Ab40 levels compared to control cells treated
with BACE inhibitor alone, reminiscent of the Ab rise
seen in APPwt cells.
Discussion
Attenuating Ab production, for instance by inhibiting
either of the respective proteases BACE-1 or g-secretase,
is considered an attractive strategy for preventing dis-
ease progression in patients suffering from Alzheimer’s
Disease. However, both of these protease inhibition
approaches have met several challenges over recent
years. BACE-1 has been a difficult target from a chemi-
cal tractability point of view with few compounds enter-
ing clinical development, most likely due to the
difficulties in achieving the combination of necessary
enzyme inhibition with adequate brain exposure. More-
over, compounds that target g-secretase have been asso-
ciated with severe side effects since several other
substrates with likely physiological relevance are cleaved
by the g-secretase complex. When compound exposure
wanes, treatment with g-secretase inhibitors actually
results in increased Ab levels, a so called Ab rebound/
rise. Considering these facts we felt it important to
investigate whether combining a BACE inhibitor with a
g-secretase inhibitor would result in synergistic efficacy
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Figure 3 Effect of LY450139 on Ab secretion in SH-SY5Y cells.
A. In SH-SY5Y APPwt cells (closed circles), LY450139 produced a
biphasic response with Ab40-levels increasing in response to low
concentrations of inhibitor, reaching 60% above baseline at 3 nM,
while at higher concentrations Ab40 levels started to decrease with
an approximate IC50 of 90 nM. In APPswe-transfected SH-SY5Y cells
(open circles), LY450139 produced a monophasic concentration-
dependent inhibition of Ab40-secretion with an IC50 of 18 nM. B.
LY450139 (3 nM) increased Ab42 levels by 70% as compared to
control in SH-SY5Y APPwt cells, whereas Ab42 levels in APPswe cells
were not affected.
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rebound/rise evoked by a g-secretase inhibitor.
In our first set of experiments, we were able to verify
that LY450139 increases both Ab40 and Ab42 levels at
a low concentration in SH-SY5Y APPwt cells but not in
SH-SY5Y APPswe cells. At higher concentrations, inhi-
bition occurred with LY450139 being 5-fold less potent
at inhibiting Ab secretion when using APPwt cells com-
pared to APPswe cells. The potency of LY450139 using
APPwt cells was similar to data reported from others
[10] and the 5-fold shift in potency was very similar to
Burton et al. [12], although they studied the g-secretase
inhibitor DAPT. This potency shift is presumably due to
the differences in substrate/enzyme ratios.
The Ab rise/rebound has been claimed to involve sub-
strate accumulation due to inhibition of the g-secretase
complex. The rationale being that after inhibition has
subsided the accumulated substrate, BACE-1 cleaved
fragment C99, can more readily be converted to Ab
resulting in the Ab rebound. However, sub-inhibitory
doses of g-secretase inhibitor also appear to increase Ab
levels suggesting instead that an Ab rise occurs at low
concentrations without previous inhibition [12]. Since
the aim of this paper was to examine the effect of com-
bining a g-secretase inhibitor with a BACE inhibitor, we
felt it important to first further elucidate whether a
rebound-like effect or an Ab rise was occurring in
response to g-secretase inhibition before addressing the
combination of inhibitors.
If an Ab rebound mechanism was behind the
increased Ab levels seen in our studies in vitro,t h e n
one would expect to see increased Ab levels in the cell
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Figure 4 Washout experiments with LY450139 in SH-SY5Y cells. Inhibition with high concentration of g-secretase inhibitor LY450139 leads
to substrate accumulation and decreased Ab secretion but no rebound is detected after washing out the inhibitor. SH-SY5Y APPwt cells were
treated with vehicle (0.1% DMSO) or 300 nM LY450139 for 24 h, after which the medium was collected for Ab40 (A)o rA b42 (B) measurements
(black bars). The media was replaced with fresh medium for another 24 h, and again collected for Ab40 (A)o rA b42 (B) measurements (grey
bars). C. All three bands detected with 6E10 antibody increased in density in the cells treated with 3, 30 or 300 nM LY450139 indicating
substrate accumulation. D. Densitometric quantification of data in C as means ± SEM, n = 2.
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of compound leading to g-secretase inhibiton followed
by washout. We tested this hypothesis in SH-SY5Y
APPwt cells. Despite obvious substrate accumulation
and decreased Ab secretion in response to g-secretase
inhibition, subsequent over-production of Ab was not
detected when the inhibitor was washed out. We
checked even shorter time points in case over-produc-
tion would have occurred in a transient manner but this
was not the case.
Burton et al. [12] suggested that the Ab rise would
only occur under conditions where g-secretase substrate
levels are relatively low (i.e. SH-SY5Y APPwt cells). We
tested this hypothesis by first giving an inhibitory con-
centration of LY450139 (300 nM) which resulted in sub-
strate accumulation and thus higher substrate levels in
APPwt cells and then replaced the medium with a low
concentration of LY450139 (3 nM) which normally gives
an Ab rise in low-substrate conditions. However, despite
the increased substrate levels, 3 nM LY450139 resulted
in a similar Ab rise as under control conditions without
substrate accumulation. This could perhaps be due to
the level of substrate not reaching levels present in for
instance APPswe cells. Indeed, we were not able to
detect an Ab rise in APPswe cells consistent with pre-
vious reports [12]. Alternatively, the level of substrate
does not affect the Ab rise and other mechanisms are
involved.
The results from the current paper suggest that g-
secretase inhibitors like LY450139 actually increase Ab
levels at low concentrations in vitro without the need of
prior inhibition or substrate accumulation occurring.
This phenomenon is thus better referred to as an Ab
rise taking place at low concentrations as also suggested
by others [9,12].
Having established the mode of action of LY450139 in
vitro (although not the detailed molecular mechanism),
we next studied how a BACE inhibitor affects the
LY450139-evoked Ab rise and LY450139 inhibitory
potency in SH-SY5Y APPwt and APPswe cells. The
BACE inhibitor prevented the Ab rise in a concentra-
tion-dependent manner in APPwt cells, although the
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Figure 6 Combining BACE- and g-secretase inhibitor in SH-
SY5Y APPwt cells. A. SH-SY5Y APPwt cells were treated with the
BACE-inhibitor alone or in combination with 3 or 30 nM g-secretase
inhibitor LY450139 for 24 h. Ab40 levels were subsequently
measured in the medium with ELISA. The BACE inhibitor produced
a concentration-dependent inhibition of Ab40-secretion with it’s
potency shifted to the right in the presence of 3 nM LY450139. B.
The same data as in Figure 6A but depicted in a different manner.
Here one can see how various concentrations of the BACE inhibitor
(0: open bars, 3 nM: grey bars, 30 nM: black bars) affect the
response to 0, 3 and 30 nM LY450139. The figure highlights that the
LY450139-evoked Ab40 rise is still present but attenuated in the
presence of 3 nM of the BACE inhibitor. 30 nM BACE inhibitor is
required to abolish the LY450139-evoked Ab40 rise completely.
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Page 7 of 9BACE inhibitor potency was shifted to the right (from 7
nM to 23 nM) in the presence of 3 nM LY450139, the
concentration that normally increases Ab secretion. The
concentration-dependent inhibition suggests that
ongoing BACE-1 activity is required for the Ab rise to
occur. This offers further support that the g-secretase
inhibitor-induced increases in Ab levels are not due to
rebound effects in response to substrate accumulation (i.
e. C99 fragment) since this mechanism would not likely
be BACE-1 dependent. Combining a BACE inhibitor
with 30 nM LY450139 did not have any obvious advan-
tage in APPwt cells, the BACE inhibitor potency being
more or less the same as in the presence of BACE inhi-
b i t o ra l o n e( 1 0n Mv s . 7n M ) .L Y 4 5 0 1 3 9a tt h ec o n c e n -
tration of 30 nM does not per se affect secreted Ab.
Interestingly, despite the lack of an Ab rise in SH-
SY5Y APPswe cells, 3 nM of LY450139 clearly shifted
the BACE inhibitor concentration-response curve to the
right (18 nM vs. 110 nM). This suggests that also in
APPswe cells, a low concentration of LY450139 is trying
to raise Ab levels but not enough to detect under basal
conditions. However, it appears to be manifested in the
presence of the BACE inhibitor, not by increasing Ab
levels but by counteracting BACE inhibition. Indeed,
small signs of an Ab rise in response to 3 nM LY450139
can be seen in the presence of 3 and 30 nM BACE inhi-
bitor in APPswe cells. It is possible that as g-secretase
substrate falls in response to BACE inhibition, an Ab40
rise is triggered in response to low concentrations of
LY450139 even in APPswe cells. By contrast, higher
concentrations of LY450139 (30 nM), shifted the BACE
inhibitor curve to the left, but it is important to keep in
mind that this concentration of LY450139 per se has
considerable inhibitory effects making conclusions on
possible synergy difficult. The current study thus fails to
detect any obvious synergies between g-secretase and
BACE-1 inhibition in SH-SY5Y APPwt- or in APPswe-
transfected cells. However, closer titration of inhibitors
is warranted in future studies, for instance using a
higher concentration of LY450139 (e.g. 60 nM).
Conclusions
Combined BACE-1 and g-secretase inhibition is complex
and the outcome is likely to vary depending on substrate
levels. When viewing the results from g-secretase per-
spective, BACE-1 inhibition can prevent the Ab rise
evoked by g-secretase inhibition at low concentrations
without showing any obvious potentiation at higher con-
centrations. By contrast, from a BACE-1 perspective,
adding the g-secretase inhibitor LY450139 did not
potentiate BACE-mediated inhibition but rather shifted
the concentration-response curve to the right, most
likely due to LY450139 trying to raise Ab levels at low
concentrations. Hence, adding a BACE inhibitor to a g-
secretase inhibitor like LY450139 could have advantages
by preventing the Ab rise.
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